LZLinfeng Zheng

Linfeng Zheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Linfeng Zheng has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Guoping Cheng

    Department of Pathology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China

    3 shared publications
  • Jialin Luo

    Department of Radiation Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China

    2 shared publications
  • Luying Liu

    Zhejiang cancer hospital 10 , Hangzhou, China

    2 shared publications
  • Yanru Feng

    Calgary, Alberta

    2 shared publications
  • Yuan Zhu

    Department of Radiation Oncology, Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), The Cancer Hospital of the University of Chinese Academy of Sciences, Chinese Academy of Sciences, Hangzhou, China

    2 shared publications
  • Lei Lei

    Department of Nephrology, Center of Kidney and Urology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Programmed death-ligand 1 and mammalian target of rapamycin signaling pathway in locally advanced rectal cancer

    by Yanru Feng, Jialin Luo, Peng Liu, Yuan Zhu, Guoping Cheng, Linfeng Zheng, Luying Liu

    Purpose: To evaluate the role of programmed death-ligand 1 (PD-L1) and mammalian target of rapamycin (mTOR) signaling pathway in locally advanced rectal cancer (LARC).Methods: Between February 2012 and February 2018, 103 patients with LARC treated by neoadjuvant chemoradiotherapy (neoCRT) and total mesorectal excision (TME) were included. PD-L1, mTOR and p-mTOR of pair-matched pre-neoCRT biopsies and post-neoCRT surgical tissue were evaluated by immunohistochemistry.Results: The mean combined positive score (CPS), tumor proportion score (TPS) and immune cell score (IC) of pre-neoCRT were 2.24 (0–70), 1.87 (0–70) and 0.67 (0–10), respectively. The mean CPS, TPS and IC of post-neoCRT were 2.19 (0–80), 1.38 (0–80) and 1.60 (0–20), respectively. Significant difference was observed in terms of IC between pre-neoCRT and post-neoCRT (p = 0.010). The 5-year disease-free survival (DFS) rate of the whole group was 62.4%. Multivariate analysis by Cox model indicated that pre-neoCRT TPS [hazard ratio (HR) 1.052, 95% confidence interval (CI) 1.020–1.086, p = 0.001] and post-neoCRT CPS (HR 0.733, 95% CI 0.555–0.967, p = 0.028) were associated with DFS. In the 89 patients without pathological complete response, p-mTOR and IC were upregulated after neoCRT.Conclusions: For patients with LARC treated by neoCRT and TME, p-mTOR and IC were upregulated after neoCRT. Pre-neoCRT TPS and post-neoCRT CPS were independent prognostic predictors of DFS.


  • Open Access

    Glasgow prognostic score and combined positive score for locally advanced rectal cancer

    by Yanru Feng, Jialin Luo, Peng Liu, Luying Liu, Yuan Zhu, Guoping Cheng, Linfeng Zheng

    Feng Y, et al. Ann Surg Treat Res. 2022 Mar;102(3):153-158. https://doi.org/10.4174/astr.2022.102.3.153


  • Optimizing the Energy Efficiency of Switched-Capacitor Converters in Multiprocessor System-on-Chips with a Preset DVFS Policy

    by Linfeng Zheng, Pingqiang Zhou

    Some multiprocessor system-on-chips (MPSoCs) provide designers with workload information in early chip planning stage to optimize the chip's performance. In our work, we focus on the energy efficiency of switched-capacitor converters (SCCs) in MPSoCs to efficiently support dynamic voltage and frequency scaling (DVFS). Two things motivate us to propose our design flow in MPSoCs, i.e. 1) Recent work allocates Metal-Insulator-Metal (MIM) capacitance and selects a converter ratio for each SCC to reach a higher energy efficiency. However, it brings the high overhead of its hardware implementation for various voltage and current demands. 2) DVFS policy has an unbalance distribution of its scaling decisions, which further results in an unbalance distribution of the voltage and current demands. Based on these, in our design flow, the hotspot recognition and the look-up table techniques help us to overcome the shortcomings of the recent work and harvest the benefits of the recent work. The experiment explores the different hotspot capacities' effects on energy efficiency and overhead.

  • Open Access

    Significant expression of CHK1 and p53 in bladder urothelial carcinoma as potential therapeutic targets and prognosis

    by Linfeng Zheng, Yuping Zhu, Lei Lei, Wenyong Sun, Guoping Cheng, Shifeng Yang

    Checkpoint kinase 1 (CHK1) and p53 are involved in cell‑cycle checkpoint, and cellular response to DNA damage. CHK1 and p53 are overexpressed in bladder urothelial carcinoma (BUC); however, a clear elucidation on their interaction and influence in the progress of BUC is absent. The aim of the present study was to examine the correlation between CHK1 and p53 in BUC, and analyze their value as therapeutic targets and prognostic indicators in BUC. A clinically annotated cohort of 110 patients with BUC was identified retrospectively. EnVision‑based immunohistochemistry and western blot analysis of the aforementioned DNA repair proteins were conducted on formalin‑fixed‑paraffin‑embedded or frozen tissues from the primary tumor. A total of 45 peritumoral tissue cases were assessed similarly as the control group. In the cohort of 110 patients with BUC, a significant overexpression of CHK1 and p53 was observed in primary compared with the peritumoral tissues (P<0.05). CHK1 and p53 demonstrated a positive correlation in BUC, and both were positively associated with the histological grade, clinical pathological staging, lymphatic metastasis and the 5‑year survival rate (P<0.05). However, CHK1 and p53 were not associated with sex, age, tumor diameter, single/multiple sites or incipient/recurrence. The overexpression of CHK1 and p53, and their synergistic interaction were putatively correlated with the physiology of BUC that may be deemed as potential therapeutic targets and prognostic indicators.